Impact of Cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: Delineation of thermodynamic and transporter related events using the reciprocal permeability approach

Journal of Pharmaceutical Sciences

Volumn 96, Issue 2, 2007, Pages 280-293

  Katneni, Kasiram ^a   Charman, Susan A ^a   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Excipients; P glycoprotein; Permeability; Solubility; Surfactants; Transporters

Indexed keywords

CREMOPHOR; DIGOXIN; GLYCOPROTEIN P; ORTHOVANADIC ACID; POLYSORBATE 80;

ANIMAL EXPERIMENT; ARTICLE; DRUG ABSORPTION; DRUG PENETRATION; DRUG TRANSPORT; MALE; NONHUMAN; RAT; SMALL INTESTINE ABSORPTION; THERMODYNAMICS;

EID: 33847407473     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20779     Document Type: Article

References (50)

1. Takahashi Y, Kondo H, Yasuda T, Watanabe T, Kobayashi S, Yokohama S. 2002. Common solubilizers to estimate the Caco-2 transport of poorly water-soluble drugs. Int J Pharm 246:85-94.
2. Aungst BJ, Nguyen NH, Bulgarenlli JP, Oates-Lenz K. 2000. The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharm Res 17:1175-1180.
3. Saha P, Kou JH. 2000. Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers. Eur J Pharm Biopharm 50:403-411.
4. Rege BD, Kao JP, Polli JE. 2002. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 16:237-246.
5. Lowes S, Cavet ME, Simmons NL. 2003. Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers. Eur J Pharmacol 458:49-56.
6. Hunter J, Hirst BH, Simmons NL. 1993. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res 10:743-749.
7. Hugger ED, Novak BL, Burton PS, Audus KL, Borchardt RT. 2002. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 91:1991-2002.
8. Chiu YY, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL. 2003. Human jejunal permeability of cyclosporin A: Influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res 20:749-756.
9. Bogman K, Erne-Brand F, Alsenz J, Drewe J. 2003. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J Pharm Sci 92:1250-1261.
10. Rangel-Yagui CO, Pessoa A Jr, Tavares LC. 2005. Micellar solubilization of drugs. J Pharm Pharm Sci 8:147-165.
11. Katneni K, Charman SA, Porter CJH. 2006. Permeability assessment of poorly water soluble compounds under solubilizing conditions: The reciprocal permeability approach. J Pharm Sci 95:2170-2185.
12. Shono Y, Nishihara H, Matsuda Y, Furukawa S, Okada N, Fujita T, Yamamoto A. 2004. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J Pharm Sci 93:877-885.
13. Zhang H, Yao M, Morrison RA, Chong S. 2003. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res 26:768-772.
14. Wandel C, Kim RB, Stein CM. 2003. "Inactive" excipients such as Cremophor can affect in vivo drug disposition. Clin Pharmacol Ther 73:394-396.
15. Tayrouz Y, Ding R, Burhenne J, Riedel KD, Weiss J, Hoppe-Tichy T, Haefeli WE, Mikus G. 2003. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther 73:397-405.
16. Sababi M, Borga O, Hultkvist-Bengtsson U. 2001. The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats. Eur J Pharm Sci 14:21-27.
17. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153.
18. Cornaire G, Woodley JF, Saivin S, Legendre JY, Decourt S, Cloarec A, Houin G. 2000. Effect of polyoxyl 35 castor oil and Polysorbate 80 on the intestinal absorption of digoxin in vitro. Arzneimittelforschung 50:576-579.
19. Johnson BM, Charman WN, Porter CJ. 2002. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci 4:E40.
20. Ungell AL, Andreasson A, Lundin K, Utter L. 1992. Effects of enzymatic inhibition and increased paracellular shunting on transport of vasopressin analogues in the rat. J Pharm Sci 81:640-645.
21. Lifschitz CH, Mahoney DH. 1989. Low-dose methotrexate-induced changes in intestinal permeability determined by polyethylene glycol polymers. J Pediatr Gastroenterol Nutr 9:301-306.
22. Mine Y, Zhang JW. 2003. Surfactants enhance the tight-junction permeability of food allergens in human intestinal epithelial Caco-2 cells. Int Arch Allergy Immunol 130:135-142.
23. Anderberg EK, Artursson P. 1993. Epithelial transport of drugs in cell culture. VIII: Effects of sodium dodecyl sulfate on cell membrane and tight junction permeability in human intestinal epithelial (Caco-2) cells. J Pharm Sci 82:392-398.
24. Bermejo M, Ruiz-Garcia A. 2002. Oral Permeability Predictions - From In Silico to In Vivo Models. Business Briefing: Pharmatech available online at www.touchbriefings.com.
25. Amidon GE, Higuchi WI, Ho NF. 1982. Theoretical and experimental studies of transport of micelle-solubilized solutes. J Pharm Sci 71:77-84.
26. Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. 2004. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 278:119-131.
27. Tamura S, Ohike A, Ibuki R, Amidon GL, Yamashita S. 2002. Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 91:719-729.
28. Nerurkar MM, Ho NF, Burton PS, Vidmar TJ, Borchardt RT. 1997. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J Pharm Sci 86:813-821.
29. Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A, Winnike R, Coffin M. 1999. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res 16:1812-1817.
30. Stephens RH, O'Neill CA, Warhurst A, Carlson GL, Rowland M, Warhurst G. 2001. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 296:584-591.
31. Urbach V, Harvey BJ. 2001. Rapid and nongenomic reduction of intracellular [Ca(2+)] induced by aldosterone in human bronchial epithelium. J Physiol 537:267-275.
32. Wang EJ, Casciano CN, Clement RP, Johnson WW. 2000. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Dispos 28:522-528.
33. Ingels FM, Augustijns PF. 2003. Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorp-tion screening system, Caco-2. J Pharm Sci 92:1545-1558.
34. Funakoshi S, Murakami T, Yumoto R, Kiribayashi Y, Takano M. 2005. Role of organic anion transporting polypeptide 2 in pharmacokinetics of digoxin and beta-methyldigoxin in rats. J Pharm Sci 94:1196-1203.
35. Hagenbuch B, Meier PJ. 2004. Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653-665.
36. Troutman MD, Thakker DR. 2003. Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. Pharm Res 20:1192-1199.
37. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. 2005. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 116:824-829.
38. Moosavi-Movahedi AA, Hakimelahi S, Chamani J, Khodarahmi GA, Hassanzadeh F, Luo FT, Ly TW, Shia KS, Yen CF, Jain ML, Kulatheeswaran R, Xue C, Pasdar M, Hakimelahi GH. 2003. Design, synthesis, and anticancer activity of phosphonic acid diphosphate derivative of adenine-containing butenolide and its water-soluble derivatives of paclitaxel with high antitumor activity. Bioorg Med Chem 11:4303-4313.
39. Bakos E, Evers R, Szakacs G, Tusnady GE, Welker E, Szabo K, de Haas M, van Deemter L, Borst P, Varadi A, Sarkadi B. 1998. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem 273:32167-32175.
40. Urbatsch IL, Sankaran B, Weber J, Senior AE. 1995. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. J Biol Chem 270:19383-19390.
41. Rao US. 1998. Drug binding and nucleotide hydrolyzability are essential requirements in the vanadate-induced inhibition of the human P-glycoprotein ATPase. Biochemistry 37:14981-14988.
42. Karet FE, Gainza FJ, Gyory AZ, Unwin RJ, Wrong O, Tanner MJ, Nayir A, Alpay H, Santos F, Hulton SA, Bakkaloglu A, Ozen S, Cunningham MJ, di Pietro A, Walker WG, Lifton RP. 1998. Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis. Proc Natl Acad Sci USA 95:6337-6342.
43. Rebbeor JF, Connolly GC, Henson JH, Boyer JL, Ballatori N. 2000. ATP-dependent GSH and glutathione S-conjugate transport in skate liver: Role of an Mrp functional homologue. Am J Physiol Gastrointest Liver Physiol 279:G417-G425.
44. Yusa K, Tsuruo T. 1989. Reversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 49:5002-5006.
45. Taub ME, Podila L, Ely D, Almeida I. 2005. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: Influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos 33:1679-1687.
46. Vellonen KS, Honkakoski P, Urtti A. 2004. Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity. Eur J Pharm Sci 23:181-188.
47. Aszalos A, Thompson K, Yin JJ, Ross DD. 1999. Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp). Anticancer Res 19:1053-1064.
48. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
49. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. 2000. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 6:2598-2603.
50. Tamura S, Tokunaga Y, Ibuki R, Amidon GL, Sezaki H, Yamashita S. 2003. The site-specific transport and metabolism of tacrolimus in rat small intestine. J Pharmacol Exp Ther 306:310-316.